Global Angiogenesis Modulators Supply, Demand and Key Producers, 2026-2032
The global Angiogenesis Modulators market size is expected to reach $ 30240 million by 2032, rising at a market growth of 5.8% CAGR during the forecast period (2026-2032).
Angiogenesis Modulators are pharmaceutical or biologically active agents that regulate the formation, maturation, permeability, and regression of new blood vessels, with commercially marketed products currently dominated by inhibitory therapies. Their physical presentation varies by molecular modality and includes sterile clear solutions in single-use vials or prefilled syringes for intravitreal or intravenous administration, as well as oral tablets or capsules for systemic therapy. Structurally, the category mainly covers: biologics that bind VEGF-A, VEGF-B, PlGF, or dual pathways such as Ang-2/VEGF-A, including monoclonal antibodies and fusion proteins; small-molecule kinase inhibitors that block VEGFR1/2/3 and related signaling pathways; and a much smaller group of pro-angiogenic candidates still concentrated in development or niche clinical use. Their mechanism is to modulate endothelial-cell proliferation, migration, tube formation, vascular leakage, and vessel survival, thereby reshaping local blood supply and disease microenvironment. Current suppliers are primarily large pharmaceutical manufacturers, biosimilar developers, and specialist biopharma companies with capabilities in biologics manufacturing, sterile fill-finish, or targeted small-molecule production. Major application scenarios include oncology, neovascular retinal diseases such as wet age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion. In practical market terms, the commercial value of Angiogenesis Modulators is overwhelmingly concentrated in anti-angiogenic products.
Over recent years, the commercial focus of Angiogenesis Modulators has continued to shift toward segments characterized by high barriers to entry, repeated dosing, and clearer reimbursement pathways. The strongest opportunities are coming from next-generation ophthalmic anti-VEGF therapies, expansion of oncology combination regimens, and growing biosimilar penetration. In ophthalmology, faricimab, high-dose aflibercept, and multiple aflibercept and ranibizumab biosimilars are reinforcing a competitive logic centered on longer dosing intervals, improved adherence, and lower payer burden. In oncology, VEGF/VEGFR inhibitors are increasingly positioned not only as standalone anti-vascular agents but also as backbone components in combinations with immunotherapy, chemotherapy, PARP inhibitors, and locoregional treatment. At the same time, population aging is enlarging the patient pool for wet AMD, DME, and RVO-related disease, while rising cancer prevalence and longer treatment duration continue to support demand. Growth therefore comes not only from new molecules, but also from formulation upgrades, prefilled delivery systems, regional access expansion, hospital switching, and reimbursement optimization.
The challenges and restraints are equally visible. First, competition in mature angiogenesis-related indications is already intense, with originator products facing pressure from both biosimilars and same-class competitors, leading to sustained pricing and tender pressure. Second, the benefit of anti-angiogenic therapy remains highly indication-specific and dependent on line of therapy and combination design, while long-term use is constrained by resistance, variable efficacy, and safety management issues such as hypertension, bleeding, proteinuria, thrombosis, impaired wound healing, and intraocular inflammation. Third, even in large ophthalmology markets, conversion dynamics depend heavily on specialist prescribing behavior, injection burden, real-world tolerability, and reimbursement policy; in oncology, usage is strongly shaped by guideline position, evidence quality in combination regimens, and payer negotiations. Fourth, the pro-angiogenic side still has limited commercial conversion, meaning that although the topic name covers all ?modulators,? large-scale recurring revenue remains overwhelmingly concentrated in the inhibitory side.
Downstream demand is moving in three clear directions. The first is a shift from simple efficacy toward durability, lower injection frequency, and better fit with outpatient workflow, which is accelerating the move from conventional monoclonal antibodies toward bispecific antibodies, high-dose fusion proteins, and longer-acting delivery approaches in ophthalmology. The second is a transition from single-pathway targeting to use as a mechanistic module within combination therapy, especially in liver cancer, colorectal cancer, renal cell carcinoma, and lung cancer, where anti-VEGF/VEGFR therapies increasingly function as foundational partners in broader regimens. The third is a move from originator-dominated markets to multi-supplier systems. As biosimilars enter, hospitals and payers become more sensitive to access, budget control, sterile manufacturing quality, cold-chain reliability, and real-world evidence. Future growth will therefore not be driven by volume alone, but by a reallocation of share according to durability, affordability, supply reliability, and evidence strength.
This report studies the global Angiogenesis Modulators production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Angiogenesis Modulators and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Angiogenesis Modulators that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Angiogenesis Modulators total production and demand, 2021-2032, (K Units)
Global Angiogenesis Modulators total production value, 2021-2032, (USD Million)
Global Angiogenesis Modulators production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Angiogenesis Modulators consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Angiogenesis Modulators domestic production, consumption, key domestic manufacturers and share
Global Angiogenesis Modulators production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Angiogenesis Modulators production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Angiogenesis Modulators production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Angiogenesis Modulators market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Regeneron, Bayer, Novartis, Eli Lilly, Pfizer, Eisai, Exelixis, Takeda, HUTCHMED, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Angiogenesis Modulators market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Angiogenesis Modulators Market, By Region:
1. How big is the global Angiogenesis Modulators market?
2. What is the demand of the global Angiogenesis Modulators market?
3. What is the year over year growth of the global Angiogenesis Modulators market?
4. What is the production and production value of the global Angiogenesis Modulators market?
5. Who are the key producers in the global Angiogenesis Modulators market?
6. What are the growth factors driving the market demand?
Angiogenesis Modulators are pharmaceutical or biologically active agents that regulate the formation, maturation, permeability, and regression of new blood vessels, with commercially marketed products currently dominated by inhibitory therapies. Their physical presentation varies by molecular modality and includes sterile clear solutions in single-use vials or prefilled syringes for intravitreal or intravenous administration, as well as oral tablets or capsules for systemic therapy. Structurally, the category mainly covers: biologics that bind VEGF-A, VEGF-B, PlGF, or dual pathways such as Ang-2/VEGF-A, including monoclonal antibodies and fusion proteins; small-molecule kinase inhibitors that block VEGFR1/2/3 and related signaling pathways; and a much smaller group of pro-angiogenic candidates still concentrated in development or niche clinical use. Their mechanism is to modulate endothelial-cell proliferation, migration, tube formation, vascular leakage, and vessel survival, thereby reshaping local blood supply and disease microenvironment. Current suppliers are primarily large pharmaceutical manufacturers, biosimilar developers, and specialist biopharma companies with capabilities in biologics manufacturing, sterile fill-finish, or targeted small-molecule production. Major application scenarios include oncology, neovascular retinal diseases such as wet age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion. In practical market terms, the commercial value of Angiogenesis Modulators is overwhelmingly concentrated in anti-angiogenic products.
Over recent years, the commercial focus of Angiogenesis Modulators has continued to shift toward segments characterized by high barriers to entry, repeated dosing, and clearer reimbursement pathways. The strongest opportunities are coming from next-generation ophthalmic anti-VEGF therapies, expansion of oncology combination regimens, and growing biosimilar penetration. In ophthalmology, faricimab, high-dose aflibercept, and multiple aflibercept and ranibizumab biosimilars are reinforcing a competitive logic centered on longer dosing intervals, improved adherence, and lower payer burden. In oncology, VEGF/VEGFR inhibitors are increasingly positioned not only as standalone anti-vascular agents but also as backbone components in combinations with immunotherapy, chemotherapy, PARP inhibitors, and locoregional treatment. At the same time, population aging is enlarging the patient pool for wet AMD, DME, and RVO-related disease, while rising cancer prevalence and longer treatment duration continue to support demand. Growth therefore comes not only from new molecules, but also from formulation upgrades, prefilled delivery systems, regional access expansion, hospital switching, and reimbursement optimization.
The challenges and restraints are equally visible. First, competition in mature angiogenesis-related indications is already intense, with originator products facing pressure from both biosimilars and same-class competitors, leading to sustained pricing and tender pressure. Second, the benefit of anti-angiogenic therapy remains highly indication-specific and dependent on line of therapy and combination design, while long-term use is constrained by resistance, variable efficacy, and safety management issues such as hypertension, bleeding, proteinuria, thrombosis, impaired wound healing, and intraocular inflammation. Third, even in large ophthalmology markets, conversion dynamics depend heavily on specialist prescribing behavior, injection burden, real-world tolerability, and reimbursement policy; in oncology, usage is strongly shaped by guideline position, evidence quality in combination regimens, and payer negotiations. Fourth, the pro-angiogenic side still has limited commercial conversion, meaning that although the topic name covers all ?modulators,? large-scale recurring revenue remains overwhelmingly concentrated in the inhibitory side.
Downstream demand is moving in three clear directions. The first is a shift from simple efficacy toward durability, lower injection frequency, and better fit with outpatient workflow, which is accelerating the move from conventional monoclonal antibodies toward bispecific antibodies, high-dose fusion proteins, and longer-acting delivery approaches in ophthalmology. The second is a transition from single-pathway targeting to use as a mechanistic module within combination therapy, especially in liver cancer, colorectal cancer, renal cell carcinoma, and lung cancer, where anti-VEGF/VEGFR therapies increasingly function as foundational partners in broader regimens. The third is a move from originator-dominated markets to multi-supplier systems. As biosimilars enter, hospitals and payers become more sensitive to access, budget control, sterile manufacturing quality, cold-chain reliability, and real-world evidence. Future growth will therefore not be driven by volume alone, but by a reallocation of share according to durability, affordability, supply reliability, and evidence strength.
This report studies the global Angiogenesis Modulators production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Angiogenesis Modulators and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Angiogenesis Modulators that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Angiogenesis Modulators total production and demand, 2021-2032, (K Units)
Global Angiogenesis Modulators total production value, 2021-2032, (USD Million)
Global Angiogenesis Modulators production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Angiogenesis Modulators consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Angiogenesis Modulators domestic production, consumption, key domestic manufacturers and share
Global Angiogenesis Modulators production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Angiogenesis Modulators production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Angiogenesis Modulators production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Angiogenesis Modulators market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Regeneron, Bayer, Novartis, Eli Lilly, Pfizer, Eisai, Exelixis, Takeda, HUTCHMED, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Angiogenesis Modulators market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Angiogenesis Modulators Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Angiogenesis Inhibitors
- Angiogenesis Stimulators
- Angiogenin
- Others
- Anti-angiogenic Modulators
- Pro-angiogenic Modulators
- Bidirectional or Context-dependent Modulators
- Others
- Single-target Modulators
- Dual-target Modulators
- Multi-target Modulators
- Others
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Others
- Roche
- Regeneron
- Bayer
- Novartis
- Eli Lilly
- Pfizer
- Eisai
- Exelixis
- Takeda
- HUTCHMED
- Amgen
- Sandoz
- Biocon Biologics
- Celltrion
- Samsung Bioepis
- Biogen
- Dr. Reddy?s Laboratories
- Hetero
- Intas Pharmaceuticals
- AVEO Oncology
- Innovent Biologics
- Shanghai Henlius
- Qilu Pharmaceutical
- Jiangsu Hengrui Pharmaceuticals
- Boan Biotech
- Chengdu Kanghong Pharmaceutical Group
- Genentech
- Samsung Bioepis / Biogen
- Sandoz / CIMERLI current business
- Dr. Reddy?s / Versavo
- Biocon / KRABEVA
1. How big is the global Angiogenesis Modulators market?
2. What is the demand of the global Angiogenesis Modulators market?
3. What is the year over year growth of the global Angiogenesis Modulators market?
4. What is the production and production value of the global Angiogenesis Modulators market?
5. Who are the key producers in the global Angiogenesis Modulators market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Angiogenesis Modulators Introduction
1.2 World Angiogenesis Modulators Supply & Forecast
1.2.1 World Angiogenesis Modulators Production Value (2021 & 2025 & 2032)
1.2.2 World Angiogenesis Modulators Production (2021-2032)
1.2.3 World Angiogenesis Modulators Pricing Trends (2021-2032)
1.3 World Angiogenesis Modulators Production by Region (Based on Production Site)
1.3.1 World Angiogenesis Modulators Production Value by Region (2021-2032)
1.3.2 World Angiogenesis Modulators Production by Region (2021-2032)
1.3.3 World Angiogenesis Modulators Average Price by Region (2021-2032)
1.3.4 North America Angiogenesis Modulators Production (2021-2032)
1.3.5 Europe Angiogenesis Modulators Production (2021-2032)
1.3.6 China Angiogenesis Modulators Production (2021-2032)
1.3.7 Japan Angiogenesis Modulators Production (2021-2032)
1.3.8 South Korea Angiogenesis Modulators Production (2021-2032)
1.3.9 India Angiogenesis Modulators Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Angiogenesis Modulators Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Angiogenesis Modulators Major Market Trends
2 DEMAND SUMMARY
2.1 World Angiogenesis Modulators Demand (2021-2032)
2.2 World Angiogenesis Modulators Consumption by Region
2.2.1 World Angiogenesis Modulators Consumption by Region (2021-2026)
2.2.2 World Angiogenesis Modulators Consumption Forecast by Region (2027-2032)
2.3 United States Angiogenesis Modulators Consumption (2021-2032)
2.4 China Angiogenesis Modulators Consumption (2021-2032)
2.5 Europe Angiogenesis Modulators Consumption (2021-2032)
2.6 Japan Angiogenesis Modulators Consumption (2021-2032)
2.7 South Korea Angiogenesis Modulators Consumption (2021-2032)
2.8 ASEAN Angiogenesis Modulators Consumption (2021-2032)
2.9 India Angiogenesis Modulators Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Angiogenesis Modulators Production Value by Manufacturer (2021-2026)
3.2 World Angiogenesis Modulators Production by Manufacturer (2021-2026)
3.3 World Angiogenesis Modulators Average Price by Manufacturer (2021-2026)
3.4 Angiogenesis Modulators Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Angiogenesis Modulators Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Angiogenesis Modulators in 2025
3.5.3 Global Concentration Ratios (CR8) for Angiogenesis Modulators in 2025
3.6 Angiogenesis Modulators Market: Overall Company Footprint Analysis
3.6.1 Angiogenesis Modulators Market: Region Footprint
3.6.2 Angiogenesis Modulators Market: Company Product Type Footprint
3.6.3 Angiogenesis Modulators Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Angiogenesis Modulators Production Value Comparison
4.1.1 United States VS China: Angiogenesis Modulators Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Angiogenesis Modulators Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Angiogenesis Modulators Production Comparison
4.2.1 United States VS China: Angiogenesis Modulators Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Angiogenesis Modulators Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Angiogenesis Modulators Consumption Comparison
4.3.1 United States VS China: Angiogenesis Modulators Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Angiogenesis Modulators Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Angiogenesis Modulators Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Angiogenesis Modulators Production Value (2021-2026)
4.4.3 United States Based Manufacturers Angiogenesis Modulators Production (2021-2026)
4.5 China Based Angiogenesis Modulators Manufacturers and Market Share
4.5.1 China Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Angiogenesis Modulators Production Value (2021-2026)
4.5.3 China Based Manufacturers Angiogenesis Modulators Production (2021-2026)
4.6 Rest of World Based Angiogenesis Modulators Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Angiogenesis Modulators Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Angiogenesis Modulators Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Angiogenesis Modulators Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Angiogenesis Inhibitors
5.2.2 Angiogenesis Stimulators
5.2.3 Angiogenin
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Angiogenesis Modulators Production by Type (2021-2032)
5.3.2 World Angiogenesis Modulators Production Value by Type (2021-2032)
5.3.3 World Angiogenesis Modulators Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY MECHANISM DIRECTION
6.1 World Angiogenesis Modulators Market Size Overview by Mechanism Direction: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Mechanism Direction
6.2.1 Anti-angiogenic Modulators
6.2.2 Pro-angiogenic Modulators
6.2.3 Bidirectional or Context-dependent Modulators
6.2.4 Others
6.3 Market Segment by Mechanism Direction
6.3.1 World Angiogenesis Modulators Production by Mechanism Direction (2021-2032)
6.3.2 World Angiogenesis Modulators Production Value by Mechanism Direction (2021-2032)
6.3.3 World Angiogenesis Modulators Average Price by Mechanism Direction (2021-2032)
7 MARKET ANALYSIS BY TARGET BREADTH
7.1 World Angiogenesis Modulators Market Size Overview by Target Breadth: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Target Breadth
7.2.1 Single-target Modulators
7.2.2 Dual-target Modulators
7.2.3 Multi-target Modulators
7.2.4 Others
7.3 Market Segment by Target Breadth
7.3.1 World Angiogenesis Modulators Production by Target Breadth (2021-2032)
7.3.2 World Angiogenesis Modulators Production Value by Target Breadth (2021-2032)
7.3.3 World Angiogenesis Modulators Average Price by Target Breadth (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Angiogenesis Modulators Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Breast Cancer
8.2.2 Colorectal Cancer
8.2.3 Lung Cancer
8.2.4 Prostate Cancer
8.2.5 Others
8.3 Market Segment by Application
8.3.1 World Angiogenesis Modulators Production by Application (2021-2032)
8.3.2 World Angiogenesis Modulators Production Value by Application (2021-2032)
8.3.3 World Angiogenesis Modulators Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Roche
9.1.1 Roche Details
9.1.2 Roche Major Business
9.1.3 Roche Angiogenesis Modulators Product and Services
9.1.4 Roche Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Roche Recent Developments/Updates
9.1.6 Roche Competitive Strengths & Weaknesses
9.2 Regeneron
9.2.1 Regeneron Details
9.2.2 Regeneron Major Business
9.2.3 Regeneron Angiogenesis Modulators Product and Services
9.2.4 Regeneron Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Regeneron Recent Developments/Updates
9.2.6 Regeneron Competitive Strengths & Weaknesses
9.3 Bayer
9.3.1 Bayer Details
9.3.2 Bayer Major Business
9.3.3 Bayer Angiogenesis Modulators Product and Services
9.3.4 Bayer Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Bayer Recent Developments/Updates
9.3.6 Bayer Competitive Strengths & Weaknesses
9.4 Novartis
9.4.1 Novartis Details
9.4.2 Novartis Major Business
9.4.3 Novartis Angiogenesis Modulators Product and Services
9.4.4 Novartis Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Novartis Recent Developments/Updates
9.4.6 Novartis Competitive Strengths & Weaknesses
9.5 Eli Lilly
9.5.1 Eli Lilly Details
9.5.2 Eli Lilly Major Business
9.5.3 Eli Lilly Angiogenesis Modulators Product and Services
9.5.4 Eli Lilly Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Eli Lilly Recent Developments/Updates
9.5.6 Eli Lilly Competitive Strengths & Weaknesses
9.6 Pfizer
9.6.1 Pfizer Details
9.6.2 Pfizer Major Business
9.6.3 Pfizer Angiogenesis Modulators Product and Services
9.6.4 Pfizer Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Pfizer Recent Developments/Updates
9.6.6 Pfizer Competitive Strengths & Weaknesses
9.7 Eisai
9.7.1 Eisai Details
9.7.2 Eisai Major Business
9.7.3 Eisai Angiogenesis Modulators Product and Services
9.7.4 Eisai Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Eisai Recent Developments/Updates
9.7.6 Eisai Competitive Strengths & Weaknesses
9.8 Exelixis
9.8.1 Exelixis Details
9.8.2 Exelixis Major Business
9.8.3 Exelixis Angiogenesis Modulators Product and Services
9.8.4 Exelixis Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Exelixis Recent Developments/Updates
9.8.6 Exelixis Competitive Strengths & Weaknesses
9.9 Takeda
9.9.1 Takeda Details
9.9.2 Takeda Major Business
9.9.3 Takeda Angiogenesis Modulators Product and Services
9.9.4 Takeda Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Takeda Recent Developments/Updates
9.9.6 Takeda Competitive Strengths & Weaknesses
9.10 HUTCHMED
9.10.1 HUTCHMED Details
9.10.2 HUTCHMED Major Business
9.10.3 HUTCHMED Angiogenesis Modulators Product and Services
9.10.4 HUTCHMED Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 HUTCHMED Recent Developments/Updates
9.10.6 HUTCHMED Competitive Strengths & Weaknesses
9.11 Amgen
9.11.1 Amgen Details
9.11.2 Amgen Major Business
9.11.3 Amgen Angiogenesis Modulators Product and Services
9.11.4 Amgen Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Amgen Recent Developments/Updates
9.11.6 Amgen Competitive Strengths & Weaknesses
9.12 Sandoz
9.12.1 Sandoz Details
9.12.2 Sandoz Major Business
9.12.3 Sandoz Angiogenesis Modulators Product and Services
9.12.4 Sandoz Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Sandoz Recent Developments/Updates
9.12.6 Sandoz Competitive Strengths & Weaknesses
9.13 Biocon Biologics
9.13.1 Biocon Biologics Details
9.13.2 Biocon Biologics Major Business
9.13.3 Biocon Biologics Angiogenesis Modulators Product and Services
9.13.4 Biocon Biologics Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Biocon Biologics Recent Developments/Updates
9.13.6 Biocon Biologics Competitive Strengths & Weaknesses
9.14 Celltrion
9.14.1 Celltrion Details
9.14.2 Celltrion Major Business
9.14.3 Celltrion Angiogenesis Modulators Product and Services
9.14.4 Celltrion Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Celltrion Recent Developments/Updates
9.14.6 Celltrion Competitive Strengths & Weaknesses
9.15 Samsung Bioepis
9.15.1 Samsung Bioepis Details
9.15.2 Samsung Bioepis Major Business
9.15.3 Samsung Bioepis Angiogenesis Modulators Product and Services
9.15.4 Samsung Bioepis Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Samsung Bioepis Recent Developments/Updates
9.15.6 Samsung Bioepis Competitive Strengths & Weaknesses
9.16 Biogen
9.16.1 Biogen Details
9.16.2 Biogen Major Business
9.16.3 Biogen Angiogenesis Modulators Product and Services
9.16.4 Biogen Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Biogen Recent Developments/Updates
9.16.6 Biogen Competitive Strengths & Weaknesses
9.17 Dr. Reddy?s Laboratories
9.17.1 Dr. Reddy?s Laboratories Details
9.17.2 Dr. Reddy?s Laboratories Major Business
9.17.3 Dr. Reddy?s Laboratories Angiogenesis Modulators Product and Services
9.17.4 Dr. Reddy?s Laboratories Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 Dr. Reddy?s Laboratories Recent Developments/Updates
9.17.6 Dr. Reddy?s Laboratories Competitive Strengths & Weaknesses
9.18 Hetero
9.18.1 Hetero Details
9.18.2 Hetero Major Business
9.18.3 Hetero Angiogenesis Modulators Product and Services
9.18.4 Hetero Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Hetero Recent Developments/Updates
9.18.6 Hetero Competitive Strengths & Weaknesses
9.19 Intas Pharmaceuticals
9.19.1 Intas Pharmaceuticals Details
9.19.2 Intas Pharmaceuticals Major Business
9.19.3 Intas Pharmaceuticals Angiogenesis Modulators Product and Services
9.19.4 Intas Pharmaceuticals Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.19.5 Intas Pharmaceuticals Recent Developments/Updates
9.19.6 Intas Pharmaceuticals Competitive Strengths & Weaknesses
9.20 AVEO Oncology
9.20.1 AVEO Oncology Details
9.20.2 AVEO Oncology Major Business
9.20.3 AVEO Oncology Angiogenesis Modulators Product and Services
9.20.4 AVEO Oncology Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.20.5 AVEO Oncology Recent Developments/Updates
9.20.6 AVEO Oncology Competitive Strengths & Weaknesses
9.21 Innovent Biologics
9.21.1 Innovent Biologics Details
9.21.2 Innovent Biologics Major Business
9.21.3 Innovent Biologics Angiogenesis Modulators Product and Services
9.21.4 Innovent Biologics Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.21.5 Innovent Biologics Recent Developments/Updates
9.21.6 Innovent Biologics Competitive Strengths & Weaknesses
9.22 Shanghai Henlius
9.22.1 Shanghai Henlius Details
9.22.2 Shanghai Henlius Major Business
9.22.3 Shanghai Henlius Angiogenesis Modulators Product and Services
9.22.4 Shanghai Henlius Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.22.5 Shanghai Henlius Recent Developments/Updates
9.22.6 Shanghai Henlius Competitive Strengths & Weaknesses
9.23 Qilu Pharmaceutical
9.23.1 Qilu Pharmaceutical Details
9.23.2 Qilu Pharmaceutical Major Business
9.23.3 Qilu Pharmaceutical Angiogenesis Modulators Product and Services
9.23.4 Qilu Pharmaceutical Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.23.5 Qilu Pharmaceutical Recent Developments/Updates
9.23.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
9.24 Jiangsu Hengrui Pharmaceuticals
9.24.1 Jiangsu Hengrui Pharmaceuticals Details
9.24.2 Jiangsu Hengrui Pharmaceuticals Major Business
9.24.3 Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Product and Services
9.24.4 Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.24.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
9.24.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
9.25 Boan Biotech
9.25.1 Boan Biotech Details
9.25.2 Boan Biotech Major Business
9.25.3 Boan Biotech Angiogenesis Modulators Product and Services
9.25.4 Boan Biotech Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.25.5 Boan Biotech Recent Developments/Updates
9.25.6 Boan Biotech Competitive Strengths & Weaknesses
9.26 Chengdu Kanghong Pharmaceutical Group
9.26.1 Chengdu Kanghong Pharmaceutical Group Details
9.26.2 Chengdu Kanghong Pharmaceutical Group Major Business
9.26.3 Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Product and Services
9.26.4 Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.26.5 Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
9.26.6 Chengdu Kanghong Pharmaceutical Group Competitive Strengths & Weaknesses
9.27 Genentech
9.27.1 Genentech Details
9.27.2 Genentech Major Business
9.27.3 Genentech Angiogenesis Modulators Product and Services
9.27.4 Genentech Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.27.5 Genentech Recent Developments/Updates
9.27.6 Genentech Competitive Strengths & Weaknesses
9.28 Samsung Bioepis / Biogen
9.28.1 Samsung Bioepis / Biogen Details
9.28.2 Samsung Bioepis / Biogen Major Business
9.28.3 Samsung Bioepis / Biogen Angiogenesis Modulators Product and Services
9.28.4 Samsung Bioepis / Biogen Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.28.5 Samsung Bioepis / Biogen Recent Developments/Updates
9.28.6 Samsung Bioepis / Biogen Competitive Strengths & Weaknesses
9.29 Sandoz / CIMERLI current business
9.29.1 Sandoz / CIMERLI current business Details
9.29.2 Sandoz / CIMERLI current business Major Business
9.29.3 Sandoz / CIMERLI current business Angiogenesis Modulators Product and Services
9.29.4 Sandoz / CIMERLI current business Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.29.5 Sandoz / CIMERLI current business Recent Developments/Updates
9.29.6 Sandoz / CIMERLI current business Competitive Strengths & Weaknesses
9.30 Dr. Reddy?s / Versavo
9.30.1 Dr. Reddy?s / Versavo Details
9.30.2 Dr. Reddy?s / Versavo Major Business
9.30.3 Dr. Reddy?s / Versavo Angiogenesis Modulators Product and Services
9.30.4 Dr. Reddy?s / Versavo Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.30.5 Dr. Reddy?s / Versavo Recent Developments/Updates
9.30.6 Dr. Reddy?s / Versavo Competitive Strengths & Weaknesses
9.31 Biocon / KRABEVA
9.31.1 Biocon / KRABEVA Details
9.31.2 Biocon / KRABEVA Major Business
9.31.3 Biocon / KRABEVA Angiogenesis Modulators Product and Services
9.31.4 Biocon / KRABEVA Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.31.5 Biocon / KRABEVA Recent Developments/Updates
9.31.6 Biocon / KRABEVA Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Angiogenesis Modulators Industry Chain
10.2 Angiogenesis Modulators Upstream Analysis
10.2.1 Angiogenesis Modulators Core Raw Materials
10.2.2 Main Manufacturers of Angiogenesis Modulators Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Angiogenesis Modulators Production Mode
10.6 Angiogenesis Modulators Procurement Model
10.7 Angiogenesis Modulators Industry Sales Model and Sales Channels
10.7.1 Angiogenesis Modulators Sales Model
10.7.2 Angiogenesis Modulators Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Angiogenesis Modulators Introduction
1.2 World Angiogenesis Modulators Supply & Forecast
1.2.1 World Angiogenesis Modulators Production Value (2021 & 2025 & 2032)
1.2.2 World Angiogenesis Modulators Production (2021-2032)
1.2.3 World Angiogenesis Modulators Pricing Trends (2021-2032)
1.3 World Angiogenesis Modulators Production by Region (Based on Production Site)
1.3.1 World Angiogenesis Modulators Production Value by Region (2021-2032)
1.3.2 World Angiogenesis Modulators Production by Region (2021-2032)
1.3.3 World Angiogenesis Modulators Average Price by Region (2021-2032)
1.3.4 North America Angiogenesis Modulators Production (2021-2032)
1.3.5 Europe Angiogenesis Modulators Production (2021-2032)
1.3.6 China Angiogenesis Modulators Production (2021-2032)
1.3.7 Japan Angiogenesis Modulators Production (2021-2032)
1.3.8 South Korea Angiogenesis Modulators Production (2021-2032)
1.3.9 India Angiogenesis Modulators Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Angiogenesis Modulators Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Angiogenesis Modulators Major Market Trends
2 DEMAND SUMMARY
2.1 World Angiogenesis Modulators Demand (2021-2032)
2.2 World Angiogenesis Modulators Consumption by Region
2.2.1 World Angiogenesis Modulators Consumption by Region (2021-2026)
2.2.2 World Angiogenesis Modulators Consumption Forecast by Region (2027-2032)
2.3 United States Angiogenesis Modulators Consumption (2021-2032)
2.4 China Angiogenesis Modulators Consumption (2021-2032)
2.5 Europe Angiogenesis Modulators Consumption (2021-2032)
2.6 Japan Angiogenesis Modulators Consumption (2021-2032)
2.7 South Korea Angiogenesis Modulators Consumption (2021-2032)
2.8 ASEAN Angiogenesis Modulators Consumption (2021-2032)
2.9 India Angiogenesis Modulators Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Angiogenesis Modulators Production Value by Manufacturer (2021-2026)
3.2 World Angiogenesis Modulators Production by Manufacturer (2021-2026)
3.3 World Angiogenesis Modulators Average Price by Manufacturer (2021-2026)
3.4 Angiogenesis Modulators Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Angiogenesis Modulators Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Angiogenesis Modulators in 2025
3.5.3 Global Concentration Ratios (CR8) for Angiogenesis Modulators in 2025
3.6 Angiogenesis Modulators Market: Overall Company Footprint Analysis
3.6.1 Angiogenesis Modulators Market: Region Footprint
3.6.2 Angiogenesis Modulators Market: Company Product Type Footprint
3.6.3 Angiogenesis Modulators Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Angiogenesis Modulators Production Value Comparison
4.1.1 United States VS China: Angiogenesis Modulators Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Angiogenesis Modulators Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Angiogenesis Modulators Production Comparison
4.2.1 United States VS China: Angiogenesis Modulators Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Angiogenesis Modulators Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Angiogenesis Modulators Consumption Comparison
4.3.1 United States VS China: Angiogenesis Modulators Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Angiogenesis Modulators Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Angiogenesis Modulators Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Angiogenesis Modulators Production Value (2021-2026)
4.4.3 United States Based Manufacturers Angiogenesis Modulators Production (2021-2026)
4.5 China Based Angiogenesis Modulators Manufacturers and Market Share
4.5.1 China Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Angiogenesis Modulators Production Value (2021-2026)
4.5.3 China Based Manufacturers Angiogenesis Modulators Production (2021-2026)
4.6 Rest of World Based Angiogenesis Modulators Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Angiogenesis Modulators Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Angiogenesis Modulators Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Angiogenesis Modulators Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Angiogenesis Inhibitors
5.2.2 Angiogenesis Stimulators
5.2.3 Angiogenin
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Angiogenesis Modulators Production by Type (2021-2032)
5.3.2 World Angiogenesis Modulators Production Value by Type (2021-2032)
5.3.3 World Angiogenesis Modulators Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY MECHANISM DIRECTION
6.1 World Angiogenesis Modulators Market Size Overview by Mechanism Direction: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Mechanism Direction
6.2.1 Anti-angiogenic Modulators
6.2.2 Pro-angiogenic Modulators
6.2.3 Bidirectional or Context-dependent Modulators
6.2.4 Others
6.3 Market Segment by Mechanism Direction
6.3.1 World Angiogenesis Modulators Production by Mechanism Direction (2021-2032)
6.3.2 World Angiogenesis Modulators Production Value by Mechanism Direction (2021-2032)
6.3.3 World Angiogenesis Modulators Average Price by Mechanism Direction (2021-2032)
7 MARKET ANALYSIS BY TARGET BREADTH
7.1 World Angiogenesis Modulators Market Size Overview by Target Breadth: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Target Breadth
7.2.1 Single-target Modulators
7.2.2 Dual-target Modulators
7.2.3 Multi-target Modulators
7.2.4 Others
7.3 Market Segment by Target Breadth
7.3.1 World Angiogenesis Modulators Production by Target Breadth (2021-2032)
7.3.2 World Angiogenesis Modulators Production Value by Target Breadth (2021-2032)
7.3.3 World Angiogenesis Modulators Average Price by Target Breadth (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Angiogenesis Modulators Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Breast Cancer
8.2.2 Colorectal Cancer
8.2.3 Lung Cancer
8.2.4 Prostate Cancer
8.2.5 Others
8.3 Market Segment by Application
8.3.1 World Angiogenesis Modulators Production by Application (2021-2032)
8.3.2 World Angiogenesis Modulators Production Value by Application (2021-2032)
8.3.3 World Angiogenesis Modulators Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Roche
9.1.1 Roche Details
9.1.2 Roche Major Business
9.1.3 Roche Angiogenesis Modulators Product and Services
9.1.4 Roche Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Roche Recent Developments/Updates
9.1.6 Roche Competitive Strengths & Weaknesses
9.2 Regeneron
9.2.1 Regeneron Details
9.2.2 Regeneron Major Business
9.2.3 Regeneron Angiogenesis Modulators Product and Services
9.2.4 Regeneron Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Regeneron Recent Developments/Updates
9.2.6 Regeneron Competitive Strengths & Weaknesses
9.3 Bayer
9.3.1 Bayer Details
9.3.2 Bayer Major Business
9.3.3 Bayer Angiogenesis Modulators Product and Services
9.3.4 Bayer Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Bayer Recent Developments/Updates
9.3.6 Bayer Competitive Strengths & Weaknesses
9.4 Novartis
9.4.1 Novartis Details
9.4.2 Novartis Major Business
9.4.3 Novartis Angiogenesis Modulators Product and Services
9.4.4 Novartis Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Novartis Recent Developments/Updates
9.4.6 Novartis Competitive Strengths & Weaknesses
9.5 Eli Lilly
9.5.1 Eli Lilly Details
9.5.2 Eli Lilly Major Business
9.5.3 Eli Lilly Angiogenesis Modulators Product and Services
9.5.4 Eli Lilly Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Eli Lilly Recent Developments/Updates
9.5.6 Eli Lilly Competitive Strengths & Weaknesses
9.6 Pfizer
9.6.1 Pfizer Details
9.6.2 Pfizer Major Business
9.6.3 Pfizer Angiogenesis Modulators Product and Services
9.6.4 Pfizer Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Pfizer Recent Developments/Updates
9.6.6 Pfizer Competitive Strengths & Weaknesses
9.7 Eisai
9.7.1 Eisai Details
9.7.2 Eisai Major Business
9.7.3 Eisai Angiogenesis Modulators Product and Services
9.7.4 Eisai Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Eisai Recent Developments/Updates
9.7.6 Eisai Competitive Strengths & Weaknesses
9.8 Exelixis
9.8.1 Exelixis Details
9.8.2 Exelixis Major Business
9.8.3 Exelixis Angiogenesis Modulators Product and Services
9.8.4 Exelixis Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Exelixis Recent Developments/Updates
9.8.6 Exelixis Competitive Strengths & Weaknesses
9.9 Takeda
9.9.1 Takeda Details
9.9.2 Takeda Major Business
9.9.3 Takeda Angiogenesis Modulators Product and Services
9.9.4 Takeda Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Takeda Recent Developments/Updates
9.9.6 Takeda Competitive Strengths & Weaknesses
9.10 HUTCHMED
9.10.1 HUTCHMED Details
9.10.2 HUTCHMED Major Business
9.10.3 HUTCHMED Angiogenesis Modulators Product and Services
9.10.4 HUTCHMED Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 HUTCHMED Recent Developments/Updates
9.10.6 HUTCHMED Competitive Strengths & Weaknesses
9.11 Amgen
9.11.1 Amgen Details
9.11.2 Amgen Major Business
9.11.3 Amgen Angiogenesis Modulators Product and Services
9.11.4 Amgen Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 Amgen Recent Developments/Updates
9.11.6 Amgen Competitive Strengths & Weaknesses
9.12 Sandoz
9.12.1 Sandoz Details
9.12.2 Sandoz Major Business
9.12.3 Sandoz Angiogenesis Modulators Product and Services
9.12.4 Sandoz Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Sandoz Recent Developments/Updates
9.12.6 Sandoz Competitive Strengths & Weaknesses
9.13 Biocon Biologics
9.13.1 Biocon Biologics Details
9.13.2 Biocon Biologics Major Business
9.13.3 Biocon Biologics Angiogenesis Modulators Product and Services
9.13.4 Biocon Biologics Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Biocon Biologics Recent Developments/Updates
9.13.6 Biocon Biologics Competitive Strengths & Weaknesses
9.14 Celltrion
9.14.1 Celltrion Details
9.14.2 Celltrion Major Business
9.14.3 Celltrion Angiogenesis Modulators Product and Services
9.14.4 Celltrion Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Celltrion Recent Developments/Updates
9.14.6 Celltrion Competitive Strengths & Weaknesses
9.15 Samsung Bioepis
9.15.1 Samsung Bioepis Details
9.15.2 Samsung Bioepis Major Business
9.15.3 Samsung Bioepis Angiogenesis Modulators Product and Services
9.15.4 Samsung Bioepis Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Samsung Bioepis Recent Developments/Updates
9.15.6 Samsung Bioepis Competitive Strengths & Weaknesses
9.16 Biogen
9.16.1 Biogen Details
9.16.2 Biogen Major Business
9.16.3 Biogen Angiogenesis Modulators Product and Services
9.16.4 Biogen Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Biogen Recent Developments/Updates
9.16.6 Biogen Competitive Strengths & Weaknesses
9.17 Dr. Reddy?s Laboratories
9.17.1 Dr. Reddy?s Laboratories Details
9.17.2 Dr. Reddy?s Laboratories Major Business
9.17.3 Dr. Reddy?s Laboratories Angiogenesis Modulators Product and Services
9.17.4 Dr. Reddy?s Laboratories Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.17.5 Dr. Reddy?s Laboratories Recent Developments/Updates
9.17.6 Dr. Reddy?s Laboratories Competitive Strengths & Weaknesses
9.18 Hetero
9.18.1 Hetero Details
9.18.2 Hetero Major Business
9.18.3 Hetero Angiogenesis Modulators Product and Services
9.18.4 Hetero Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.18.5 Hetero Recent Developments/Updates
9.18.6 Hetero Competitive Strengths & Weaknesses
9.19 Intas Pharmaceuticals
9.19.1 Intas Pharmaceuticals Details
9.19.2 Intas Pharmaceuticals Major Business
9.19.3 Intas Pharmaceuticals Angiogenesis Modulators Product and Services
9.19.4 Intas Pharmaceuticals Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.19.5 Intas Pharmaceuticals Recent Developments/Updates
9.19.6 Intas Pharmaceuticals Competitive Strengths & Weaknesses
9.20 AVEO Oncology
9.20.1 AVEO Oncology Details
9.20.2 AVEO Oncology Major Business
9.20.3 AVEO Oncology Angiogenesis Modulators Product and Services
9.20.4 AVEO Oncology Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.20.5 AVEO Oncology Recent Developments/Updates
9.20.6 AVEO Oncology Competitive Strengths & Weaknesses
9.21 Innovent Biologics
9.21.1 Innovent Biologics Details
9.21.2 Innovent Biologics Major Business
9.21.3 Innovent Biologics Angiogenesis Modulators Product and Services
9.21.4 Innovent Biologics Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.21.5 Innovent Biologics Recent Developments/Updates
9.21.6 Innovent Biologics Competitive Strengths & Weaknesses
9.22 Shanghai Henlius
9.22.1 Shanghai Henlius Details
9.22.2 Shanghai Henlius Major Business
9.22.3 Shanghai Henlius Angiogenesis Modulators Product and Services
9.22.4 Shanghai Henlius Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.22.5 Shanghai Henlius Recent Developments/Updates
9.22.6 Shanghai Henlius Competitive Strengths & Weaknesses
9.23 Qilu Pharmaceutical
9.23.1 Qilu Pharmaceutical Details
9.23.2 Qilu Pharmaceutical Major Business
9.23.3 Qilu Pharmaceutical Angiogenesis Modulators Product and Services
9.23.4 Qilu Pharmaceutical Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.23.5 Qilu Pharmaceutical Recent Developments/Updates
9.23.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
9.24 Jiangsu Hengrui Pharmaceuticals
9.24.1 Jiangsu Hengrui Pharmaceuticals Details
9.24.2 Jiangsu Hengrui Pharmaceuticals Major Business
9.24.3 Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Product and Services
9.24.4 Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.24.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
9.24.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
9.25 Boan Biotech
9.25.1 Boan Biotech Details
9.25.2 Boan Biotech Major Business
9.25.3 Boan Biotech Angiogenesis Modulators Product and Services
9.25.4 Boan Biotech Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.25.5 Boan Biotech Recent Developments/Updates
9.25.6 Boan Biotech Competitive Strengths & Weaknesses
9.26 Chengdu Kanghong Pharmaceutical Group
9.26.1 Chengdu Kanghong Pharmaceutical Group Details
9.26.2 Chengdu Kanghong Pharmaceutical Group Major Business
9.26.3 Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Product and Services
9.26.4 Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.26.5 Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
9.26.6 Chengdu Kanghong Pharmaceutical Group Competitive Strengths & Weaknesses
9.27 Genentech
9.27.1 Genentech Details
9.27.2 Genentech Major Business
9.27.3 Genentech Angiogenesis Modulators Product and Services
9.27.4 Genentech Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.27.5 Genentech Recent Developments/Updates
9.27.6 Genentech Competitive Strengths & Weaknesses
9.28 Samsung Bioepis / Biogen
9.28.1 Samsung Bioepis / Biogen Details
9.28.2 Samsung Bioepis / Biogen Major Business
9.28.3 Samsung Bioepis / Biogen Angiogenesis Modulators Product and Services
9.28.4 Samsung Bioepis / Biogen Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.28.5 Samsung Bioepis / Biogen Recent Developments/Updates
9.28.6 Samsung Bioepis / Biogen Competitive Strengths & Weaknesses
9.29 Sandoz / CIMERLI current business
9.29.1 Sandoz / CIMERLI current business Details
9.29.2 Sandoz / CIMERLI current business Major Business
9.29.3 Sandoz / CIMERLI current business Angiogenesis Modulators Product and Services
9.29.4 Sandoz / CIMERLI current business Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.29.5 Sandoz / CIMERLI current business Recent Developments/Updates
9.29.6 Sandoz / CIMERLI current business Competitive Strengths & Weaknesses
9.30 Dr. Reddy?s / Versavo
9.30.1 Dr. Reddy?s / Versavo Details
9.30.2 Dr. Reddy?s / Versavo Major Business
9.30.3 Dr. Reddy?s / Versavo Angiogenesis Modulators Product and Services
9.30.4 Dr. Reddy?s / Versavo Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.30.5 Dr. Reddy?s / Versavo Recent Developments/Updates
9.30.6 Dr. Reddy?s / Versavo Competitive Strengths & Weaknesses
9.31 Biocon / KRABEVA
9.31.1 Biocon / KRABEVA Details
9.31.2 Biocon / KRABEVA Major Business
9.31.3 Biocon / KRABEVA Angiogenesis Modulators Product and Services
9.31.4 Biocon / KRABEVA Angiogenesis Modulators Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.31.5 Biocon / KRABEVA Recent Developments/Updates
9.31.6 Biocon / KRABEVA Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Angiogenesis Modulators Industry Chain
10.2 Angiogenesis Modulators Upstream Analysis
10.2.1 Angiogenesis Modulators Core Raw Materials
10.2.2 Main Manufacturers of Angiogenesis Modulators Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Angiogenesis Modulators Production Mode
10.6 Angiogenesis Modulators Procurement Model
10.7 Angiogenesis Modulators Industry Sales Model and Sales Channels
10.7.1 Angiogenesis Modulators Sales Model
10.7.2 Angiogenesis Modulators Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Angiogenesis Modulators Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Angiogenesis Modulators Production Value by Region (2021-2026) & (USD Million)
Table 3. World Angiogenesis Modulators Production Value by Region (2027-2032) & (USD Million)
Table 4. World Angiogenesis Modulators Production Value Market Share by Region (2021-2026)
Table 5. World Angiogenesis Modulators Production Value Market Share by Region (2027-2032)
Table 6. World Angiogenesis Modulators Production by Region (2021-2026) & (K Units)
Table 7. World Angiogenesis Modulators Production by Region (2027-2032) & (K Units)
Table 8. World Angiogenesis Modulators Production Market Share by Region (2021-2026)
Table 9. World Angiogenesis Modulators Production Market Share by Region (2027-2032)
Table 10. World Angiogenesis Modulators Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Angiogenesis Modulators Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Angiogenesis Modulators Major Market Trends
Table 13. World Angiogenesis Modulators Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Angiogenesis Modulators Consumption by Region (2021-2026) & (K Units)
Table 15. World Angiogenesis Modulators Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Angiogenesis Modulators Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Angiogenesis Modulators Producers in 2025
Table 18. World Angiogenesis Modulators Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Angiogenesis Modulators Producers in 2025
Table 20. World Angiogenesis Modulators Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Angiogenesis Modulators Company Evaluation Quadrant
Table 22. World Angiogenesis Modulators Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Angiogenesis Modulators Production Site of Key Manufacturer
Table 24. Angiogenesis Modulators Market: Company Product Type Footprint
Table 25. Angiogenesis Modulators Market: Company Product Application Footprint
Table 26. Angiogenesis Modulators Competitive Factors
Table 27. Angiogenesis Modulators New Entrant and Capacity Expansion Plans
Table 28. Angiogenesis Modulators Mergers & Acquisitions Activity
Table 29. United States VS China Angiogenesis Modulators Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Angiogenesis Modulators Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Angiogenesis Modulators Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Angiogenesis Modulators Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Angiogenesis Modulators Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Angiogenesis Modulators Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Angiogenesis Modulators Production Market Share (2021-2026)
Table 37. China Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Angiogenesis Modulators Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Angiogenesis Modulators Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Angiogenesis Modulators Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Angiogenesis Modulators Production Market Share (2021-2026)
Table 42. Rest of World Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Angiogenesis Modulators Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Angiogenesis Modulators Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Angiogenesis Modulators Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Angiogenesis Modulators Production Market Share (2021-2026)
Table 47. World Angiogenesis Modulators Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Angiogenesis Modulators Production by Type (2021-2026) & (K Units)
Table 49. World Angiogenesis Modulators Production by Type (2027-2032) & (K Units)
Table 50. World Angiogenesis Modulators Production Value by Type (2021-2026) & (USD Million)
Table 51. World Angiogenesis Modulators Production Value by Type (2027-2032) & (USD Million)
Table 52. World Angiogenesis Modulators Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Angiogenesis Modulators Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Angiogenesis Modulators Production Value by Mechanism Direction, (USD Million), 2021 & 2025 & 2032
Table 55. World Angiogenesis Modulators Production by Mechanism Direction (2021-2026) & (K Units)
Table 56. World Angiogenesis Modulators Production by Mechanism Direction (2027-2032) & (K Units)
Table 57. World Angiogenesis Modulators Production Value by Mechanism Direction (2021-2026) & (USD Million)
Table 58. World Angiogenesis Modulators Production Value by Mechanism Direction (2027-2032) & (USD Million)
Table 59. World Angiogenesis Modulators Average Price by Mechanism Direction (2021-2026) & (US$/Unit)
Table 60. World Angiogenesis Modulators Average Price by Mechanism Direction (2027-2032) & (US$/Unit)
Table 61. World Angiogenesis Modulators Production Value by Target Breadth, (USD Million), 2021 & 2025 & 2032
Table 62. World Angiogenesis Modulators Production by Target Breadth (2021-2026) & (K Units)
Table 63. World Angiogenesis Modulators Production by Target Breadth (2027-2032) & (K Units)
Table 64. World Angiogenesis Modulators Production Value by Target Breadth (2021-2026) & (USD Million)
Table 65. World Angiogenesis Modulators Production Value by Target Breadth (2027-2032) & (USD Million)
Table 66. World Angiogenesis Modulators Average Price by Target Breadth (2021-2026) & (US$/Unit)
Table 67. World Angiogenesis Modulators Average Price by Target Breadth (2027-2032) & (US$/Unit)
Table 68. World Angiogenesis Modulators Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Angiogenesis Modulators Production by Application (2021-2026) & (K Units)
Table 70. World Angiogenesis Modulators Production by Application (2027-2032) & (K Units)
Table 71. World Angiogenesis Modulators Production Value by Application (2021-2026) & (USD Million)
Table 72. World Angiogenesis Modulators Production Value by Application (2027-2032) & (USD Million)
Table 73. World Angiogenesis Modulators Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Angiogenesis Modulators Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Roche Basic Information, Manufacturing Base and Competitors
Table 76. Roche Major Business
Table 77. Roche Angiogenesis Modulators Product and Services
Table 78. Roche Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Roche Recent Developments/Updates
Table 80. Roche Competitive Strengths & Weaknesses
Table 81. Regeneron Basic Information, Manufacturing Base and Competitors
Table 82. Regeneron Major Business
Table 83. Regeneron Angiogenesis Modulators Product and Services
Table 84. Regeneron Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Regeneron Recent Developments/Updates
Table 86. Regeneron Competitive Strengths & Weaknesses
Table 87. Bayer Basic Information, Manufacturing Base and Competitors
Table 88. Bayer Major Business
Table 89. Bayer Angiogenesis Modulators Product and Services
Table 90. Bayer Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Bayer Recent Developments/Updates
Table 92. Bayer Competitive Strengths & Weaknesses
Table 93. Novartis Basic Information, Manufacturing Base and Competitors
Table 94. Novartis Major Business
Table 95. Novartis Angiogenesis Modulators Product and Services
Table 96. Novartis Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Novartis Recent Developments/Updates
Table 98. Novartis Competitive Strengths & Weaknesses
Table 99. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 100. Eli Lilly Major Business
Table 101. Eli Lilly Angiogenesis Modulators Product and Services
Table 102. Eli Lilly Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Eli Lilly Recent Developments/Updates
Table 104. Eli Lilly Competitive Strengths & Weaknesses
Table 105. Pfizer Basic Information, Manufacturing Base and Competitors
Table 106. Pfizer Major Business
Table 107. Pfizer Angiogenesis Modulators Product and Services
Table 108. Pfizer Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Pfizer Recent Developments/Updates
Table 110. Pfizer Competitive Strengths & Weaknesses
Table 111. Eisai Basic Information, Manufacturing Base and Competitors
Table 112. Eisai Major Business
Table 113. Eisai Angiogenesis Modulators Product and Services
Table 114. Eisai Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Eisai Recent Developments/Updates
Table 116. Eisai Competitive Strengths & Weaknesses
Table 117. Exelixis Basic Information, Manufacturing Base and Competitors
Table 118. Exelixis Major Business
Table 119. Exelixis Angiogenesis Modulators Product and Services
Table 120. Exelixis Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Exelixis Recent Developments/Updates
Table 122. Exelixis Competitive Strengths & Weaknesses
Table 123. Takeda Basic Information, Manufacturing Base and Competitors
Table 124. Takeda Major Business
Table 125. Takeda Angiogenesis Modulators Product and Services
Table 126. Takeda Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Takeda Recent Developments/Updates
Table 128. Takeda Competitive Strengths & Weaknesses
Table 129. HUTCHMED Basic Information, Manufacturing Base and Competitors
Table 130. HUTCHMED Major Business
Table 131. HUTCHMED Angiogenesis Modulators Product and Services
Table 132. HUTCHMED Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. HUTCHMED Recent Developments/Updates
Table 134. HUTCHMED Competitive Strengths & Weaknesses
Table 135. Amgen Basic Information, Manufacturing Base and Competitors
Table 136. Amgen Major Business
Table 137. Amgen Angiogenesis Modulators Product and Services
Table 138. Amgen Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Amgen Recent Developments/Updates
Table 140. Amgen Competitive Strengths & Weaknesses
Table 141. Sandoz Basic Information, Manufacturing Base and Competitors
Table 142. Sandoz Major Business
Table 143. Sandoz Angiogenesis Modulators Product and Services
Table 144. Sandoz Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Sandoz Recent Developments/Updates
Table 146. Sandoz Competitive Strengths & Weaknesses
Table 147. Biocon Biologics Basic Information, Manufacturing Base and Competitors
Table 148. Biocon Biologics Major Business
Table 149. Biocon Biologics Angiogenesis Modulators Product and Services
Table 150. Biocon Biologics Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Biocon Biologics Recent Developments/Updates
Table 152. Biocon Biologics Competitive Strengths & Weaknesses
Table 153. Celltrion Basic Information, Manufacturing Base and Competitors
Table 154. Celltrion Major Business
Table 155. Celltrion Angiogenesis Modulators Product and Services
Table 156. Celltrion Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Celltrion Recent Developments/Updates
Table 158. Celltrion Competitive Strengths & Weaknesses
Table 159. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 160. Samsung Bioepis Major Business
Table 161. Samsung Bioepis Angiogenesis Modulators Product and Services
Table 162. Samsung Bioepis Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Samsung Bioepis Recent Developments/Updates
Table 164. Samsung Bioepis Competitive Strengths & Weaknesses
Table 165. Biogen Basic Information, Manufacturing Base and Competitors
Table 166. Biogen Major Business
Table 167. Biogen Angiogenesis Modulators Product and Services
Table 168. Biogen Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Biogen Recent Developments/Updates
Table 170. Biogen Competitive Strengths & Weaknesses
Table 171. Dr. Reddy?s Laboratories Basic Information, Manufacturing Base and Competitors
Table 172. Dr. Reddy?s Laboratories Major Business
Table 173. Dr. Reddy?s Laboratories Angiogenesis Modulators Product and Services
Table 174. Dr. Reddy?s Laboratories Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. Dr. Reddy?s Laboratories Recent Developments/Updates
Table 176. Dr. Reddy?s Laboratories Competitive Strengths & Weaknesses
Table 177. Hetero Basic Information, Manufacturing Base and Competitors
Table 178. Hetero Major Business
Table 179. Hetero Angiogenesis Modulators Product and Services
Table 180. Hetero Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Hetero Recent Developments/Updates
Table 182. Hetero Competitive Strengths & Weaknesses
Table 183. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 184. Intas Pharmaceuticals Major Business
Table 185. Intas Pharmaceuticals Angiogenesis Modulators Product and Services
Table 186. Intas Pharmaceuticals Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 187. Intas Pharmaceuticals Recent Developments/Updates
Table 188. Intas Pharmaceuticals Competitive Strengths & Weaknesses
Table 189. AVEO Oncology Basic Information, Manufacturing Base and Competitors
Table 190. AVEO Oncology Major Business
Table 191. AVEO Oncology Angiogenesis Modulators Product and Services
Table 192. AVEO Oncology Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 193. AVEO Oncology Recent Developments/Updates
Table 194. AVEO Oncology Competitive Strengths & Weaknesses
Table 195. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 196. Innovent Biologics Major Business
Table 197. Innovent Biologics Angiogenesis Modulators Product and Services
Table 198. Innovent Biologics Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 199. Innovent Biologics Recent Developments/Updates
Table 200. Innovent Biologics Competitive Strengths & Weaknesses
Table 201. Shanghai Henlius Basic Information, Manufacturing Base and Competitors
Table 202. Shanghai Henlius Major Business
Table 203. Shanghai Henlius Angiogenesis Modulators Product and Services
Table 204. Shanghai Henlius Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 205. Shanghai Henlius Recent Developments/Updates
Table 206. Shanghai Henlius Competitive Strengths & Weaknesses
Table 207. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 208. Qilu Pharmaceutical Major Business
Table 209. Qilu Pharmaceutical Angiogenesis Modulators Product and Services
Table 210. Qilu Pharmaceutical Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 211. Qilu Pharmaceutical Recent Developments/Updates
Table 212. Qilu Pharmaceutical Competitive Strengths & Weaknesses
Table 213. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 214. Jiangsu Hengrui Pharmaceuticals Major Business
Table 215. Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Product and Services
Table 216. Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 217. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 218. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 219. Boan Biotech Basic Information, Manufacturing Base and Competitors
Table 220. Boan Biotech Major Business
Table 221. Boan Biotech Angiogenesis Modulators Product and Services
Table 222. Boan Biotech Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 223. Boan Biotech Recent Developments/Updates
Table 224. Boan Biotech Competitive Strengths & Weaknesses
Table 225. Chengdu Kanghong Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 226. Chengdu Kanghong Pharmaceutical Group Major Business
Table 227. Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Product and Services
Table 228. Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 229. Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
Table 230. Chengdu Kanghong Pharmaceutical Group Competitive Strengths & Weaknesses
Table 231. Genentech Basic Information, Manufacturing Base and Competitors
Table 232. Genentech Major Business
Table 233. Genentech Angiogenesis Modulators Product and Services
Table 234. Genentech Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 235. Genentech Recent Developments/Updates
Table 236. Genentech Competitive Strengths & Weaknesses
Table 237. Samsung Bioepis / Biogen Basic Information, Manufacturing Base and Competitors
Table 238. Samsung Bioepis / Biogen Major Business
Table 239. Samsung Bioepis / Biogen Angiogenesis Modulators Product and Services
Table 240. Samsung Bioepis / Biogen Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 241. Samsung Bioepis / Biogen Recent Developments/Updates
Table 242. Samsung Bioepis / Biogen Competitive Strengths & Weaknesses
Table 243. Sandoz / CIMERLI current business Basic Information, Manufacturing Base and Competitors
Table 244. Sandoz / CIMERLI current business Major Business
Table 245. Sandoz / CIMERLI current business Angiogenesis Modulators Product and Services
Table 246. Sandoz / CIMERLI current business Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 247. Sandoz / CIMERLI current business Recent Developments/Updates
Table 248. Sandoz / CIMERLI current business Competitive Strengths & Weaknesses
Table 249. Dr. Reddy?s / Versavo Basic Information, Manufacturing Base and Competitors
Table 250. Dr. Reddy?s / Versavo Major Business
Table 251. Dr. Reddy?s / Versavo Angiogenesis Modulators Product and Services
Table 252. Dr. Reddy?s / Versavo Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 253. Dr. Reddy?s / Versavo Recent Developments/Updates
Table 254. Dr. Reddy?s / Versavo Competitive Strengths & Weaknesses
Table 255. Biocon / KRABEVA Basic Information, Manufacturing Base and Competitors
Table 256. Biocon / KRABEVA Major Business
Table 257. Biocon / KRABEVA Angiogenesis Modulators Product and Services
Table 258. Biocon / KRABEVA Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 259. Biocon / KRABEVA Recent Developments/Updates
Table 260. Biocon / KRABEVA Competitive Strengths & Weaknesses
Table 261. Global Key Players of Angiogenesis Modulators Upstream (Raw Materials)
Table 262. Global Angiogenesis Modulators Typical Customers
Table 263. Angiogenesis Modulators Typical Distributors
Table 1. World Angiogenesis Modulators Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Angiogenesis Modulators Production Value by Region (2021-2026) & (USD Million)
Table 3. World Angiogenesis Modulators Production Value by Region (2027-2032) & (USD Million)
Table 4. World Angiogenesis Modulators Production Value Market Share by Region (2021-2026)
Table 5. World Angiogenesis Modulators Production Value Market Share by Region (2027-2032)
Table 6. World Angiogenesis Modulators Production by Region (2021-2026) & (K Units)
Table 7. World Angiogenesis Modulators Production by Region (2027-2032) & (K Units)
Table 8. World Angiogenesis Modulators Production Market Share by Region (2021-2026)
Table 9. World Angiogenesis Modulators Production Market Share by Region (2027-2032)
Table 10. World Angiogenesis Modulators Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Angiogenesis Modulators Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Angiogenesis Modulators Major Market Trends
Table 13. World Angiogenesis Modulators Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Angiogenesis Modulators Consumption by Region (2021-2026) & (K Units)
Table 15. World Angiogenesis Modulators Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Angiogenesis Modulators Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Angiogenesis Modulators Producers in 2025
Table 18. World Angiogenesis Modulators Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Angiogenesis Modulators Producers in 2025
Table 20. World Angiogenesis Modulators Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Angiogenesis Modulators Company Evaluation Quadrant
Table 22. World Angiogenesis Modulators Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Angiogenesis Modulators Production Site of Key Manufacturer
Table 24. Angiogenesis Modulators Market: Company Product Type Footprint
Table 25. Angiogenesis Modulators Market: Company Product Application Footprint
Table 26. Angiogenesis Modulators Competitive Factors
Table 27. Angiogenesis Modulators New Entrant and Capacity Expansion Plans
Table 28. Angiogenesis Modulators Mergers & Acquisitions Activity
Table 29. United States VS China Angiogenesis Modulators Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Angiogenesis Modulators Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Angiogenesis Modulators Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Angiogenesis Modulators Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Angiogenesis Modulators Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Angiogenesis Modulators Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Angiogenesis Modulators Production Market Share (2021-2026)
Table 37. China Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Angiogenesis Modulators Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Angiogenesis Modulators Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Angiogenesis Modulators Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Angiogenesis Modulators Production Market Share (2021-2026)
Table 42. Rest of World Based Angiogenesis Modulators Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Angiogenesis Modulators Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Angiogenesis Modulators Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Angiogenesis Modulators Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Angiogenesis Modulators Production Market Share (2021-2026)
Table 47. World Angiogenesis Modulators Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Angiogenesis Modulators Production by Type (2021-2026) & (K Units)
Table 49. World Angiogenesis Modulators Production by Type (2027-2032) & (K Units)
Table 50. World Angiogenesis Modulators Production Value by Type (2021-2026) & (USD Million)
Table 51. World Angiogenesis Modulators Production Value by Type (2027-2032) & (USD Million)
Table 52. World Angiogenesis Modulators Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Angiogenesis Modulators Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Angiogenesis Modulators Production Value by Mechanism Direction, (USD Million), 2021 & 2025 & 2032
Table 55. World Angiogenesis Modulators Production by Mechanism Direction (2021-2026) & (K Units)
Table 56. World Angiogenesis Modulators Production by Mechanism Direction (2027-2032) & (K Units)
Table 57. World Angiogenesis Modulators Production Value by Mechanism Direction (2021-2026) & (USD Million)
Table 58. World Angiogenesis Modulators Production Value by Mechanism Direction (2027-2032) & (USD Million)
Table 59. World Angiogenesis Modulators Average Price by Mechanism Direction (2021-2026) & (US$/Unit)
Table 60. World Angiogenesis Modulators Average Price by Mechanism Direction (2027-2032) & (US$/Unit)
Table 61. World Angiogenesis Modulators Production Value by Target Breadth, (USD Million), 2021 & 2025 & 2032
Table 62. World Angiogenesis Modulators Production by Target Breadth (2021-2026) & (K Units)
Table 63. World Angiogenesis Modulators Production by Target Breadth (2027-2032) & (K Units)
Table 64. World Angiogenesis Modulators Production Value by Target Breadth (2021-2026) & (USD Million)
Table 65. World Angiogenesis Modulators Production Value by Target Breadth (2027-2032) & (USD Million)
Table 66. World Angiogenesis Modulators Average Price by Target Breadth (2021-2026) & (US$/Unit)
Table 67. World Angiogenesis Modulators Average Price by Target Breadth (2027-2032) & (US$/Unit)
Table 68. World Angiogenesis Modulators Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Angiogenesis Modulators Production by Application (2021-2026) & (K Units)
Table 70. World Angiogenesis Modulators Production by Application (2027-2032) & (K Units)
Table 71. World Angiogenesis Modulators Production Value by Application (2021-2026) & (USD Million)
Table 72. World Angiogenesis Modulators Production Value by Application (2027-2032) & (USD Million)
Table 73. World Angiogenesis Modulators Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Angiogenesis Modulators Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Roche Basic Information, Manufacturing Base and Competitors
Table 76. Roche Major Business
Table 77. Roche Angiogenesis Modulators Product and Services
Table 78. Roche Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Roche Recent Developments/Updates
Table 80. Roche Competitive Strengths & Weaknesses
Table 81. Regeneron Basic Information, Manufacturing Base and Competitors
Table 82. Regeneron Major Business
Table 83. Regeneron Angiogenesis Modulators Product and Services
Table 84. Regeneron Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Regeneron Recent Developments/Updates
Table 86. Regeneron Competitive Strengths & Weaknesses
Table 87. Bayer Basic Information, Manufacturing Base and Competitors
Table 88. Bayer Major Business
Table 89. Bayer Angiogenesis Modulators Product and Services
Table 90. Bayer Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Bayer Recent Developments/Updates
Table 92. Bayer Competitive Strengths & Weaknesses
Table 93. Novartis Basic Information, Manufacturing Base and Competitors
Table 94. Novartis Major Business
Table 95. Novartis Angiogenesis Modulators Product and Services
Table 96. Novartis Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Novartis Recent Developments/Updates
Table 98. Novartis Competitive Strengths & Weaknesses
Table 99. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 100. Eli Lilly Major Business
Table 101. Eli Lilly Angiogenesis Modulators Product and Services
Table 102. Eli Lilly Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Eli Lilly Recent Developments/Updates
Table 104. Eli Lilly Competitive Strengths & Weaknesses
Table 105. Pfizer Basic Information, Manufacturing Base and Competitors
Table 106. Pfizer Major Business
Table 107. Pfizer Angiogenesis Modulators Product and Services
Table 108. Pfizer Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Pfizer Recent Developments/Updates
Table 110. Pfizer Competitive Strengths & Weaknesses
Table 111. Eisai Basic Information, Manufacturing Base and Competitors
Table 112. Eisai Major Business
Table 113. Eisai Angiogenesis Modulators Product and Services
Table 114. Eisai Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Eisai Recent Developments/Updates
Table 116. Eisai Competitive Strengths & Weaknesses
Table 117. Exelixis Basic Information, Manufacturing Base and Competitors
Table 118. Exelixis Major Business
Table 119. Exelixis Angiogenesis Modulators Product and Services
Table 120. Exelixis Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Exelixis Recent Developments/Updates
Table 122. Exelixis Competitive Strengths & Weaknesses
Table 123. Takeda Basic Information, Manufacturing Base and Competitors
Table 124. Takeda Major Business
Table 125. Takeda Angiogenesis Modulators Product and Services
Table 126. Takeda Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Takeda Recent Developments/Updates
Table 128. Takeda Competitive Strengths & Weaknesses
Table 129. HUTCHMED Basic Information, Manufacturing Base and Competitors
Table 130. HUTCHMED Major Business
Table 131. HUTCHMED Angiogenesis Modulators Product and Services
Table 132. HUTCHMED Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. HUTCHMED Recent Developments/Updates
Table 134. HUTCHMED Competitive Strengths & Weaknesses
Table 135. Amgen Basic Information, Manufacturing Base and Competitors
Table 136. Amgen Major Business
Table 137. Amgen Angiogenesis Modulators Product and Services
Table 138. Amgen Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Amgen Recent Developments/Updates
Table 140. Amgen Competitive Strengths & Weaknesses
Table 141. Sandoz Basic Information, Manufacturing Base and Competitors
Table 142. Sandoz Major Business
Table 143. Sandoz Angiogenesis Modulators Product and Services
Table 144. Sandoz Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Sandoz Recent Developments/Updates
Table 146. Sandoz Competitive Strengths & Weaknesses
Table 147. Biocon Biologics Basic Information, Manufacturing Base and Competitors
Table 148. Biocon Biologics Major Business
Table 149. Biocon Biologics Angiogenesis Modulators Product and Services
Table 150. Biocon Biologics Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Biocon Biologics Recent Developments/Updates
Table 152. Biocon Biologics Competitive Strengths & Weaknesses
Table 153. Celltrion Basic Information, Manufacturing Base and Competitors
Table 154. Celltrion Major Business
Table 155. Celltrion Angiogenesis Modulators Product and Services
Table 156. Celltrion Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Celltrion Recent Developments/Updates
Table 158. Celltrion Competitive Strengths & Weaknesses
Table 159. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 160. Samsung Bioepis Major Business
Table 161. Samsung Bioepis Angiogenesis Modulators Product and Services
Table 162. Samsung Bioepis Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Samsung Bioepis Recent Developments/Updates
Table 164. Samsung Bioepis Competitive Strengths & Weaknesses
Table 165. Biogen Basic Information, Manufacturing Base and Competitors
Table 166. Biogen Major Business
Table 167. Biogen Angiogenesis Modulators Product and Services
Table 168. Biogen Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Biogen Recent Developments/Updates
Table 170. Biogen Competitive Strengths & Weaknesses
Table 171. Dr. Reddy?s Laboratories Basic Information, Manufacturing Base and Competitors
Table 172. Dr. Reddy?s Laboratories Major Business
Table 173. Dr. Reddy?s Laboratories Angiogenesis Modulators Product and Services
Table 174. Dr. Reddy?s Laboratories Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 175. Dr. Reddy?s Laboratories Recent Developments/Updates
Table 176. Dr. Reddy?s Laboratories Competitive Strengths & Weaknesses
Table 177. Hetero Basic Information, Manufacturing Base and Competitors
Table 178. Hetero Major Business
Table 179. Hetero Angiogenesis Modulators Product and Services
Table 180. Hetero Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 181. Hetero Recent Developments/Updates
Table 182. Hetero Competitive Strengths & Weaknesses
Table 183. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 184. Intas Pharmaceuticals Major Business
Table 185. Intas Pharmaceuticals Angiogenesis Modulators Product and Services
Table 186. Intas Pharmaceuticals Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 187. Intas Pharmaceuticals Recent Developments/Updates
Table 188. Intas Pharmaceuticals Competitive Strengths & Weaknesses
Table 189. AVEO Oncology Basic Information, Manufacturing Base and Competitors
Table 190. AVEO Oncology Major Business
Table 191. AVEO Oncology Angiogenesis Modulators Product and Services
Table 192. AVEO Oncology Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 193. AVEO Oncology Recent Developments/Updates
Table 194. AVEO Oncology Competitive Strengths & Weaknesses
Table 195. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 196. Innovent Biologics Major Business
Table 197. Innovent Biologics Angiogenesis Modulators Product and Services
Table 198. Innovent Biologics Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 199. Innovent Biologics Recent Developments/Updates
Table 200. Innovent Biologics Competitive Strengths & Weaknesses
Table 201. Shanghai Henlius Basic Information, Manufacturing Base and Competitors
Table 202. Shanghai Henlius Major Business
Table 203. Shanghai Henlius Angiogenesis Modulators Product and Services
Table 204. Shanghai Henlius Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 205. Shanghai Henlius Recent Developments/Updates
Table 206. Shanghai Henlius Competitive Strengths & Weaknesses
Table 207. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 208. Qilu Pharmaceutical Major Business
Table 209. Qilu Pharmaceutical Angiogenesis Modulators Product and Services
Table 210. Qilu Pharmaceutical Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 211. Qilu Pharmaceutical Recent Developments/Updates
Table 212. Qilu Pharmaceutical Competitive Strengths & Weaknesses
Table 213. Jiangsu Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 214. Jiangsu Hengrui Pharmaceuticals Major Business
Table 215. Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Product and Services
Table 216. Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 217. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 218. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 219. Boan Biotech Basic Information, Manufacturing Base and Competitors
Table 220. Boan Biotech Major Business
Table 221. Boan Biotech Angiogenesis Modulators Product and Services
Table 222. Boan Biotech Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 223. Boan Biotech Recent Developments/Updates
Table 224. Boan Biotech Competitive Strengths & Weaknesses
Table 225. Chengdu Kanghong Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 226. Chengdu Kanghong Pharmaceutical Group Major Business
Table 227. Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Product and Services
Table 228. Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 229. Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
Table 230. Chengdu Kanghong Pharmaceutical Group Competitive Strengths & Weaknesses
Table 231. Genentech Basic Information, Manufacturing Base and Competitors
Table 232. Genentech Major Business
Table 233. Genentech Angiogenesis Modulators Product and Services
Table 234. Genentech Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 235. Genentech Recent Developments/Updates
Table 236. Genentech Competitive Strengths & Weaknesses
Table 237. Samsung Bioepis / Biogen Basic Information, Manufacturing Base and Competitors
Table 238. Samsung Bioepis / Biogen Major Business
Table 239. Samsung Bioepis / Biogen Angiogenesis Modulators Product and Services
Table 240. Samsung Bioepis / Biogen Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 241. Samsung Bioepis / Biogen Recent Developments/Updates
Table 242. Samsung Bioepis / Biogen Competitive Strengths & Weaknesses
Table 243. Sandoz / CIMERLI current business Basic Information, Manufacturing Base and Competitors
Table 244. Sandoz / CIMERLI current business Major Business
Table 245. Sandoz / CIMERLI current business Angiogenesis Modulators Product and Services
Table 246. Sandoz / CIMERLI current business Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 247. Sandoz / CIMERLI current business Recent Developments/Updates
Table 248. Sandoz / CIMERLI current business Competitive Strengths & Weaknesses
Table 249. Dr. Reddy?s / Versavo Basic Information, Manufacturing Base and Competitors
Table 250. Dr. Reddy?s / Versavo Major Business
Table 251. Dr. Reddy?s / Versavo Angiogenesis Modulators Product and Services
Table 252. Dr. Reddy?s / Versavo Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 253. Dr. Reddy?s / Versavo Recent Developments/Updates
Table 254. Dr. Reddy?s / Versavo Competitive Strengths & Weaknesses
Table 255. Biocon / KRABEVA Basic Information, Manufacturing Base and Competitors
Table 256. Biocon / KRABEVA Major Business
Table 257. Biocon / KRABEVA Angiogenesis Modulators Product and Services
Table 258. Biocon / KRABEVA Angiogenesis Modulators Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 259. Biocon / KRABEVA Recent Developments/Updates
Table 260. Biocon / KRABEVA Competitive Strengths & Weaknesses
Table 261. Global Key Players of Angiogenesis Modulators Upstream (Raw Materials)
Table 262. Global Angiogenesis Modulators Typical Customers
Table 263. Angiogenesis Modulators Typical Distributors
LIST OF FIGURES
Figure 1. Angiogenesis Modulators Picture
Figure 2. World Angiogenesis Modulators Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Angiogenesis Modulators Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 5. World Angiogenesis Modulators Average Price (2021-2032) & (US$/Unit)
Figure 6. World Angiogenesis Modulators Production Value Market Share by Region (2021-2032)
Figure 7. World Angiogenesis Modulators Production Market Share by Region (2021-2032)
Figure 8. North America Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 9. Europe Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 10. China Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 11. Japan Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 12. South Korea Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 13. India Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 14. Angiogenesis Modulators Market Drivers
Figure 15. Factors Affecting Demand
Figure 16. World Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 17. World Angiogenesis Modulators Consumption Market Share by Region (2021-2032)
Figure 18. United States Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 19. China Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 20. Europe Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 21. Japan Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 22. South Korea Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 23. ASEAN Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 24. India Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 25. Producer Shipments of Angiogenesis Modulators by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 26. Global Four-firm Concentration Ratios (CR4) for Angiogenesis Modulators Markets in 2025
Figure 27. Global Four-firm Concentration Ratios (CR8) for Angiogenesis Modulators Markets in 2025
Figure 28. United States VS China: Angiogenesis Modulators Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Angiogenesis Modulators Production Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States VS China: Angiogenesis Modulators Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 31. United States Based Manufacturers Angiogenesis Modulators Production Market Share 2025
Figure 32. China Based Manufacturers Angiogenesis Modulators Production Market Share 2025
Figure 33. Rest of World Based Manufacturers Angiogenesis Modulators Production Market Share 2025
Figure 34. World Angiogenesis Modulators Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 35. World Angiogenesis Modulators Production Value Market Share by Type in 2025
Figure 36. Angiogenesis Inhibitors
Figure 37. Angiogenesis Stimulators
Figure 38. Angiogenin
Figure 39. Others
Figure 40. World Angiogenesis Modulators Production Market Share by Type (2021-2032)
Figure 41. World Angiogenesis Modulators Production Value Market Share by Type (2021-2032)
Figure 42. World Angiogenesis Modulators Average Price by Type (2021-2032) & (US$/Unit)
Figure 43. World Angiogenesis Modulators Production Value by Mechanism Direction, (USD Million), 2021 & 2025 & 2032
Figure 44. World Angiogenesis Modulators Production Value Market Share by Mechanism Direction in 2025
Figure 45. Anti-angiogenic Modulators
Figure 46. Pro-angiogenic Modulators
Figure 47. Bidirectional or Context-dependent Modulators
Figure 48. Others
Figure 49. World Angiogenesis Modulators Production Market Share by Mechanism Direction (2021-2032)
Figure 50. World Angiogenesis Modulators Production Value Market Share by Mechanism Direction (2021-2032)
Figure 51. World Angiogenesis Modulators Average Price by Mechanism Direction (2021-2032) & (US$/Unit)
Figure 52. World Angiogenesis Modulators Production Value by Target Breadth, (USD Million), 2021 & 2025 & 2032
Figure 53. World Angiogenesis Modulators Production Value Market Share by Target Breadth in 2025
Figure 54. Single-target Modulators
Figure 55. Dual-target Modulators
Figure 56. Multi-target Modulators
Figure 57. Others
Figure 58. World Angiogenesis Modulators Production Market Share by Target Breadth (2021-2032)
Figure 59. World Angiogenesis Modulators Production Value Market Share by Target Breadth (2021-2032)
Figure 60. World Angiogenesis Modulators Average Price by Target Breadth (2021-2032) & (US$/Unit)
Figure 61. World Angiogenesis Modulators Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 62. World Angiogenesis Modulators Production Value Market Share by Application in 2025
Figure 63. Breast Cancer
Figure 64. Colorectal Cancer
Figure 65. Lung Cancer
Figure 66. Prostate Cancer
Figure 67. Others
Figure 68. World Angiogenesis Modulators Production Market Share by Application (2021-2032)
Figure 69. World Angiogenesis Modulators Production Value Market Share by Application (2021-2032)
Figure 70. World Angiogenesis Modulators Average Price by Application (2021-2032) & (US$/Unit)
Figure 71. Angiogenesis Modulators Industry Chain
Figure 72. Angiogenesis Modulators Procurement Model
Figure 73. Angiogenesis Modulators Sales Model
Figure 74. Angiogenesis Modulators Sales Channels, Direct Sales, and Distribution
Figure 75. Methodology
Figure 76. Research Process and Data Source
Figure 1. Angiogenesis Modulators Picture
Figure 2. World Angiogenesis Modulators Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Angiogenesis Modulators Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 5. World Angiogenesis Modulators Average Price (2021-2032) & (US$/Unit)
Figure 6. World Angiogenesis Modulators Production Value Market Share by Region (2021-2032)
Figure 7. World Angiogenesis Modulators Production Market Share by Region (2021-2032)
Figure 8. North America Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 9. Europe Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 10. China Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 11. Japan Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 12. South Korea Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 13. India Angiogenesis Modulators Production (2021-2032) & (K Units)
Figure 14. Angiogenesis Modulators Market Drivers
Figure 15. Factors Affecting Demand
Figure 16. World Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 17. World Angiogenesis Modulators Consumption Market Share by Region (2021-2032)
Figure 18. United States Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 19. China Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 20. Europe Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 21. Japan Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 22. South Korea Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 23. ASEAN Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 24. India Angiogenesis Modulators Consumption (2021-2032) & (K Units)
Figure 25. Producer Shipments of Angiogenesis Modulators by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 26. Global Four-firm Concentration Ratios (CR4) for Angiogenesis Modulators Markets in 2025
Figure 27. Global Four-firm Concentration Ratios (CR8) for Angiogenesis Modulators Markets in 2025
Figure 28. United States VS China: Angiogenesis Modulators Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: Angiogenesis Modulators Production Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States VS China: Angiogenesis Modulators Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 31. United States Based Manufacturers Angiogenesis Modulators Production Market Share 2025
Figure 32. China Based Manufacturers Angiogenesis Modulators Production Market Share 2025
Figure 33. Rest of World Based Manufacturers Angiogenesis Modulators Production Market Share 2025
Figure 34. World Angiogenesis Modulators Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 35. World Angiogenesis Modulators Production Value Market Share by Type in 2025
Figure 36. Angiogenesis Inhibitors
Figure 37. Angiogenesis Stimulators
Figure 38. Angiogenin
Figure 39. Others
Figure 40. World Angiogenesis Modulators Production Market Share by Type (2021-2032)
Figure 41. World Angiogenesis Modulators Production Value Market Share by Type (2021-2032)
Figure 42. World Angiogenesis Modulators Average Price by Type (2021-2032) & (US$/Unit)
Figure 43. World Angiogenesis Modulators Production Value by Mechanism Direction, (USD Million), 2021 & 2025 & 2032
Figure 44. World Angiogenesis Modulators Production Value Market Share by Mechanism Direction in 2025
Figure 45. Anti-angiogenic Modulators
Figure 46. Pro-angiogenic Modulators
Figure 47. Bidirectional or Context-dependent Modulators
Figure 48. Others
Figure 49. World Angiogenesis Modulators Production Market Share by Mechanism Direction (2021-2032)
Figure 50. World Angiogenesis Modulators Production Value Market Share by Mechanism Direction (2021-2032)
Figure 51. World Angiogenesis Modulators Average Price by Mechanism Direction (2021-2032) & (US$/Unit)
Figure 52. World Angiogenesis Modulators Production Value by Target Breadth, (USD Million), 2021 & 2025 & 2032
Figure 53. World Angiogenesis Modulators Production Value Market Share by Target Breadth in 2025
Figure 54. Single-target Modulators
Figure 55. Dual-target Modulators
Figure 56. Multi-target Modulators
Figure 57. Others
Figure 58. World Angiogenesis Modulators Production Market Share by Target Breadth (2021-2032)
Figure 59. World Angiogenesis Modulators Production Value Market Share by Target Breadth (2021-2032)
Figure 60. World Angiogenesis Modulators Average Price by Target Breadth (2021-2032) & (US$/Unit)
Figure 61. World Angiogenesis Modulators Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 62. World Angiogenesis Modulators Production Value Market Share by Application in 2025
Figure 63. Breast Cancer
Figure 64. Colorectal Cancer
Figure 65. Lung Cancer
Figure 66. Prostate Cancer
Figure 67. Others
Figure 68. World Angiogenesis Modulators Production Market Share by Application (2021-2032)
Figure 69. World Angiogenesis Modulators Production Value Market Share by Application (2021-2032)
Figure 70. World Angiogenesis Modulators Average Price by Application (2021-2032) & (US$/Unit)
Figure 71. Angiogenesis Modulators Industry Chain
Figure 72. Angiogenesis Modulators Procurement Model
Figure 73. Angiogenesis Modulators Sales Model
Figure 74. Angiogenesis Modulators Sales Channels, Direct Sales, and Distribution
Figure 75. Methodology
Figure 76. Research Process and Data Source
